Paris - Delayed Quote ? EUR AB Science S.A. (AB.PA) Follow Compare 0.9660 +0.0310 (+3.32%) At close: 5:35 PM GMT+2 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for AB.PA 1D 5D -0.62% 1M -1.53% 3M -9.04% 6M -50.91% YTD -72.83% 1Y -60.33% 2Y -88.49% 5Y -75.54% All -92.56% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: AB.PA View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS GlobeNewswire ? 5 days ago AB Science: Revenues for the first half of 2024 and update on AB Science’s activities GlobeNewswire ? 12 days ago AB Science announces a slight delay in the publication of its 2024 half-year financial report GlobeNewswire ? 22 days ago AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement GlobeNewswire ? 26 days ago AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024 GlobeNewswire ? 29 days ago AB Science touts positive Phase II Covid-19 data for masitinib Clinical Trials Arena ? 3 months ago AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19 GlobeNewswire ? 3 months ago AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS GlobeNewswire ? 4 months ago AB Science reports its revenues for the year 2023 and provides an update on its activities GlobeNewswire ? 5 months ago AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036 GlobeNewswire ? 5 months ago AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient GlobeNewswire ? 5 months ago View More Related Tickers ALM.MC Almirall, S.A. 9.26 +0.60% ? CYTH Cyclo Therapeutics, Inc. 0.7720 -4.69% ? CRON Cronos Group Inc. 2.2900 +7.51% ? LNTH Lantheus Holdings, Inc. 112.63 +0.49% ? BHC Bausch Health Companies Inc. 8.11 -0.73% ? AKAN Akanda Corp. 1.0000 -6.54% ? TLRY Tilray Brands, Inc. 1.7100 +8.23% ?
